JP2021512966A5 - - Google Patents

Download PDF

Info

Publication number
JP2021512966A5
JP2021512966A5 JP2020564972A JP2020564972A JP2021512966A5 JP 2021512966 A5 JP2021512966 A5 JP 2021512966A5 JP 2020564972 A JP2020564972 A JP 2020564972A JP 2020564972 A JP2020564972 A JP 2020564972A JP 2021512966 A5 JP2021512966 A5 JP 2021512966A5
Authority
JP
Japan
Prior art keywords
vaccine composition
cancer
seq
therapy
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512966A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050089 external-priority patent/WO2019153042A1/en
Publication of JP2021512966A publication Critical patent/JP2021512966A/ja
Publication of JP2021512966A5 publication Critical patent/JP2021512966A5/ja
Pending legal-status Critical Current

Links

JP2020564972A 2018-02-07 2019-02-07 ワクチン組成物およびその使用 Pending JP2021512966A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2018900368 2018-02-07
AU2018900368A AU2018900368A0 (en) 2018-02-07 A vaccine composition and uses thereof
AU2018903518 2018-09-19
AU2018903518A AU2018903518A0 (en) 2018-09-19 A vaccine composition and uses thereof
AU2018903968 2018-10-19
AU2018903968A AU2018903968A0 (en) 2018-10-19 A vaccine composition and uses thereof
PCT/AU2019/050089 WO2019153042A1 (en) 2018-02-07 2019-02-07 A vaccine composition and uses thereof

Publications (2)

Publication Number Publication Date
JP2021512966A JP2021512966A (ja) 2021-05-20
JP2021512966A5 true JP2021512966A5 (https=) 2021-11-25

Family

ID=67547868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564972A Pending JP2021512966A (ja) 2018-02-07 2019-02-07 ワクチン組成物およびその使用

Country Status (7)

Country Link
US (1) US12311019B2 (https=)
EP (1) EP3749356A4 (https=)
JP (1) JP2021512966A (https=)
CN (1) CN112203681B (https=)
AU (1) AU2019216873B2 (https=)
CA (1) CA3090552A1 (https=)
WO (1) WO2019153042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4393947A4 (en) * 2021-08-25 2025-07-30 Toagosei Co Ltd ANTI-PD-1 SIGNAL PEPTIDE ANTIBODY AND ITS USE
KR102401860B1 (ko) * 2021-10-21 2022-05-24 을지대학교 산학협력단 신규 항암 백신 조성물 및 그를 이용한 백신화 방법
KR102421307B1 (ko) * 2021-11-19 2022-07-14 을지대학교 산학협력단 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056591A1 (es) * 2005-10-28 2007-10-10 Vaxinnate Corp Polipeptidos ligandos para receptor 4 simil toll (tlr4)
US20120082687A1 (en) * 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
NZ717682A (en) * 2012-02-16 2017-10-27 Vlp Therapeutics Llc Virus like particle composition
CN110563850A (zh) * 2012-04-30 2019-12-13 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
CN105431449B (zh) * 2013-04-05 2021-08-24 港大科桥有限公司 新的pd1同种型及其用于加强免疫应答的用途
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
JP6824154B2 (ja) * 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC 修飾エンベロープタンパク質e3を含むウイルス様粒子
EP3916017A1 (en) * 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
TWI740823B (zh) * 2015-04-17 2021-10-01 澳大利亞商保健樂科技昆士蘭有限公司 疫苗組成物及其用途
WO2016183469A1 (en) * 2015-05-13 2016-11-17 Robert Kirken Anti-ctla-4 blockade
CN114605548A (zh) * 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CN110636855B (zh) 2017-03-28 2024-08-09 俄亥俄州创新基金会 人pd1肽疫苗及其用途

Similar Documents

Publication Publication Date Title
US7820180B2 (en) Listeria-based and LLO-based vaccines
TWI232753B (en) Adjuvant compositions comprising QS-21,3D-MPL and CpG and vaccine compositions comprising the same
US7662396B2 (en) Compositions and methods for enhancing the immunogenicity of antigens
JP5597197B2 (ja) 非溶血性llo融合タンパク質およびそれを利用する方法
AU2002244337B2 (en) Vaccines
US20080124354A1 (en) Methods for administering tumor vaccines
JP2007508272A (ja) インターロイキン18およびサポニンアジュバント系を含むワクチン組成物
US8895017B2 (en) HER-2 peptides and vaccines
JP2021512966A5 (https=)
JP5307859B2 (ja) ワクチン
AU2005232396B2 (en) Vaccination against malignant melanoma using BCG and/or vaccinia
JP2008285487A (ja) ワクチン
Lenarczyk et al. ISCOM® based vaccines for cancer immunotherapy
CN111295200B (zh) 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
JP6385280B2 (ja) 自家癌細胞ワクチン
TWI740823B (zh) 疫苗組成物及其用途
WO2009127666A2 (en) Method and compositions
Loosmore et al. Protein-Based Vaccines
Karyampudi et al. Effectiveness of Idiotype-Adjuvant Conjugate Vaccine Against a B-Cell Lymphoma
Ramakrishna et al. EGFRvIII Vaccine-specific Induction of Humoral and Cell-Mediated Immunity
MXPA06003861A (es) Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina